Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.

Epstein-Barr virus (EBV) is a ubiquitous human virus which infects almost all humans during their lifetime and following the acute phase, persists for the remainder of the life of the individual. EBV infects B lymphocytes leading to their immortalisation, with persistence of the EBV genome as an episome. In the latent phase, EBV is prevented from reactivating through efficient cytotoxic cellular immunity. EBV reactivates (lytic phase) under conditions of psychological stress with consequent weakening of cellular immunity, and EBV reactivation has been shown to occur in a subset of individuals with each of a variety of cancers, autoimmune diseases, the autoimmune-like disease, chronic fatigue syndrome/myalgic encephalitis and under other circumstances such as being an inpatient in an intensive care unit. Chronic EBV reactivation is an important mechanism in the pathogenesis of many such diseases, yet is rarely tested for in immunocompetent individuals. This review summarises the pathogenesis of EBV infection, EBV reactivation and its role in disease, and methods which may be used to detect it. Known inhibitors of EBV reactivation and replication are discussed, including drugs licensed for treatment of other herpesviruses, licensed or experimental drugs for various other indications, compounds at an early stage of drug development and nutritional constituents such as vitamins and dietary supplements.

Two new aspects of continuity of care.

OBJECTIVE: To determine whether the original continuity of care framework is still applicable to family medicine today. DESIGN: Qualitative descriptive study. SETTING: Kingston, Ont. PARTICIPANTS: Three groups of first-year family medicine residents (18 in total), 2 groups of family physicians in established comprehensive practices (9 in total), and 2 groups of family physicians working in episodic care settings (10 in total). METHODS: Using focus groups, a semistructured discussion guide, and a qualitative descriptive design, we explored the residents' and practising physicians' conceptions about continuity of care. Qualitative content analysis was used to identify themes. MAIN FINDINGS: Focus group participants consisting of family physicians providing comprehensive care, episodic care physicians, and family medicine residents exposed 2 new dimensions of continuity of care-community continuity of care (the physicians' roles in understanding the lives of their patients, and how this affects their overall health) and continuity of care within the health care team (the continuity between a patient and members of the interprofessional team, including the family physician). Geographic continuity of care (the care of a patient in various settings by the same physician) was not prominently discussed, perhaps reflecting the paucity of family physicians in the hospital setting. CONCLUSION: Both of these new dimensions of continuity of care are consistent with the ongoing evolution of family medicine as a discipline, and have important implications for how family medicine training programs should be designed to best prepare trainees for future practice.